PTC Therapeutics
PTCT
174 hedge funds and large institutions have $2.21B invested in PTC Therapeutics in 2019 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 77 increasing their positions, 36 reducing their positions, and 22 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 36
45% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 22
32% more capital invested
Capital invested by funds: $1.67B → $2.21B (+$535M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12% more call options, than puts
Call options by funds: $10M | Put options by funds: $8.99M
6% more funds holding
Funds holding: 164 → 174 (+10)
3.8% more ownership
Funds ownership: 96.65% → 100.45% (+3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$48.4M |
| 2 |
Janus Henderson Group
London,
|
+$47.6M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$36.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.9M |
| 5 |
RI
RTW Investments
New York
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$38.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$13M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.3M |
| 4 |
PP
PDT Partners
New York
|
-$9.53M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.2M |
PTCT Hedge Fund Activity: Q1 2019 in Review
174 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2019, worth a combined $2.21B — up 32% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new PTCT positions and 22 closed out — a net gain of 10 holders — while 77 added to existing stakes and 36 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $48.4M. The largest seller was Boxer Capital, cutting an estimated $38.8M.
- 174 institutional investors held PTC Therapeutics (PTCT) as of Q1 2019, up from 164 in Q4 2018.
- Funds reported $2.21B of PTC Therapeutics stock for Q1 2019, up 32% quarter-over-quarter.
- 32 funds opened new PTC Therapeutics positions in Q1 2019 and 22 closed out, a net change of +10 holders.
- The largest PTC Therapeutics buyer in Q1 2019 was Point72 Asset Management, an estimated $48.4M added.
- The largest PTC Therapeutics seller in Q1 2019 was Boxer Capital, an estimated $38.8M sold.
Based on aggregated 13F filings for Q1 2019.